In The Newsalzheon2024-08-09T11:20:07-04:00

In the News

Why lecanemab’s success spells the revival of small-molecule Alzheimer’s treatments

c&en

Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc.

Newsweek Investment Reports

‘It’s night and day’: Biogen’s new Alzheimer’s drug may spur more investment in fighting the disease

The Boston Globe

I interview Dr. Martin Tolar, Founder, CEO and President of Alzheon on the Phase 3 trial going on right now

Generation Bold

Biotech and Business Development Leader Wendy Nelson on Living With the APOE4 Gene

beingpatient.com

Alzheon’s Pill For Alzheimer’s Recruits for Clinical Trials

beingpatient.com

Alzheon Biomarker Trial Brings Insight to Stalled Treatment Space

biospace.com

Alzheimer’s Drug Developer Alzheon Secures $50 Million

WSJ